Retinal Vein Occlusion Clinical Trials

6 recruiting

Retinal Vein Occlusion Trials at a Glance

12 actively recruiting trials for retinal vein occlusion are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Amarillo, Ann Arbor, and Asheville. Lead sponsors running retinal vein occlusion studies include Annexin Pharmaceuticals AB, Bayer, and A/Prof Andrew Chang.

Browse retinal vein occlusion trials by phase

Treatments under study

About Retinal Vein Occlusion Clinical Trials

Looking for clinical trials for Retinal Vein Occlusion? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retinal Vein Occlusion trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retinal Vein Occlusion clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Not Applicable

Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies

Diabetic RetinopathyRetinal Vein Occlusion
CHU de Reims120 enrolled1 locationNCT03680794
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting

National Eye Institute Biorepository for Retinal Diseases

Age-Related Macular DegenerationDiabetic RetinopathyRetinal Disease+2 more
National Eye Institute (NEI)650 enrolled1 locationNCT01496625
Recruiting
Not Applicable

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Diabetic RetinopathyHypertension,EssentialRetinal Vein Occlusion+1 more
Johns Hopkins University1,050 enrolled1 locationNCT04505618
Recruiting
Phase 4

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment

Retinal Vein Occlusion (RVO)
First Affiliated Hospital of Chongqing Medical University120 enrolled1 locationNCT07133438
Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Hoffmann-La Roche1,000 enrolled41 locationsNCT06439576
Recruiting
Early Phase 1

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Macular DegenerationDiabetic RetinopathyRetinal Vein Occlusion+1 more
MediBeacon10 enrolled1 locationNCT04008121
Recruiting
Phase 2

Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion

Non-Proliferative Diabetic RetinopathyRetinal Vein Occlusion
Annexin Pharmaceuticals AB12 enrolled1 locationNCT07259928
Recruiting
Phase 2

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting
Phase 3

Combination of Ranibizumab and Targeted Laser Photocoagulation

Central Retinal Vein Occlusion With Macular Edema
University of Giessen110 enrolled15 locationsNCT04444492
Recruiting
Phase 4

Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusions

macular oedema secondary to retinal vein occlusion
A/Prof Andrew Chang50 enrolled1 locationACTRN12617001487303
Recruiting
Phase 2

Bevacizumab intravitreal injection in the treatment of patients with Central Retinal Vein Occlusion.

Central retinal vein occlusion (CRVO)
Royal Adelaide Hospital22 enrolled1 locationACTRN12611000300976